Have a feature idea you'd love to see implemented? Let us know!

TECH BIO-TECHNE Corp

Price (delayed)

$74.51

Market cap

$11.84B

P/E Ratio

78.43

Dividend/share

$0.32

EPS

$0.95

Enterprise value

$12.05B

Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company's ...

Highlights
BIO-TECHNE's debt has decreased by 27% YoY and by 4.9% QoQ
The quick ratio has increased by 17% since the previous quarter and by 4.7% year-on-year
The net income has decreased by 39% YoY and by 10% from the previous quarter
TECH's EPS is down by 39% year-on-year and by 11% since the previous quarter

Key stats

What are the main financial stats of TECH
Market
Shares outstanding
158.89M
Market cap
$11.84B
Enterprise value
$12.05B
Valuations
Price to book (P/B)
5.53
Price to sales (P/S)
10.08
EV/EBIT
62.75
EV/EBITDA
39.72
EV/Sales
10.29
Earnings
Revenue
$1.17B
EBIT
$192.04M
EBITDA
$303.35M
Free cash flow
$245.03M
Per share
EPS
$0.95
Free cash flow per share
$1.55
Book value per share
$13.48
Revenue per share
$7.39
TBVPS
$7.99
Balance sheet
Total assets
$2.74B
Total liabilities
$597.37M
Debt
$398.92M
Equity
$2.14B
Working capital
$506.44M
Liquidity
Debt to equity
0.19
Current ratio
4.56
Quick ratio
2.89
Net debt/EBITDA
0.7
Margins
EBITDA margin
25.9%
Gross margin
65.5%
Net margin
12.9%
Operating margin
16.3%
Efficiency
Return on assets
5.5%
Return on equity
7.4%
Return on invested capital
13.7%
Return on capital employed
7.4%
Return on sales
16.4%
Dividend
Dividend yield
0.43%
DPS
$0.32
Payout ratio
33.7%

TECH stock price

How has the BIO-TECHNE stock price performed over time
Intraday
0.84%
1 week
-1.13%
1 month
-1.74%
1 year
12.83%
YTD
-3.43%
QTD
-6.78%

Financial performance

How have BIO-TECHNE's revenue and profit performed over time
Revenue
$1.17B
Gross profit
$767.55M
Operating income
$190.81M
Net income
$150.71M
Gross margin
65.5%
Net margin
12.9%
BIO-TECHNE's net margin has decreased by 40% YoY and by 11% QoQ
The net income has decreased by 39% YoY and by 10% from the previous quarter
BIO-TECHNE's operating margin has decreased by 38% YoY and by 8% QoQ
The company's operating income fell by 36% YoY and by 8% QoQ

Growth

What is BIO-TECHNE's growth rate over time

Valuation

What is BIO-TECHNE stock price valuation
P/E
78.43
P/B
5.53
P/S
10.08
EV/EBIT
62.75
EV/EBITDA
39.72
EV/Sales
10.29
TECH's EPS is down by 39% year-on-year and by 11% since the previous quarter
TECH's P/E is 26% above its 5-year quarterly average of 62.2 and 20% above its last 4 quarters average of 65.3
The stock's price to book (P/B) is 26% less than its 5-year quarterly average of 7.5 and 4.7% less than its last 4 quarters average of 5.8
BIO-TECHNE's equity has increased by 7% YoY and by 3.4% from the previous quarter
The price to sales (P/S) is 22% lower than the 5-year quarterly average of 13.0
The revenue has grown by 2.4% YoY

Efficiency

How efficient is BIO-TECHNE business performance
BIO-TECHNE's return on equity has decreased by 42% YoY and by 12% QoQ
TECH's return on assets is down by 42% year-on-year and by 11% since the previous quarter
BIO-TECHNE's ROIC has decreased by 40% YoY and by 2.8% from the previous quarter
TECH's return on sales is down by 36% year-on-year and by 6% since the previous quarter

Dividends

What is TECH's dividend history
DPS
$0.32
Dividend yield
0.43%
Payout ratio
33.7%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did BIO-TECHNE financials performed over time
BIO-TECHNE's total liabilities has decreased by 21% YoY and by 6% QoQ
TECH's current ratio is up by 18% from the previous quarter
BIO-TECHNE's debt is 81% lower than its equity
TECH's debt to equity is down by 32% year-on-year and by 5% since the previous quarter
BIO-TECHNE's debt has decreased by 27% YoY and by 4.9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.